Douglas Galasko
Works at
University of California, San Diego
Professor in residence
Sources: reporter.nih.gov
Grants and prizes
U01, In vitro pharmacology, chronic toxicology, and embryo-fetal development studies to demonstrate safety of GSM-779690, U01AG094588, 2025–2027, 3 Aug 2026
National Institute of Neurological Disorders and Stroke
U01, Amyloid clearing therapy in dementia with Lewy bodies plus Alzheimers disease (ACT DLB+), U01NS145959, 2026–2033, 28 Jul 2026
The Michael J. Fox Foundation for Parkinson's Research
Neuronal Synuclein Disease Endotypes 2024, Assessing the Aggregation of Alpha-synuclein Across Aging, Alzheimer’s Disease and Dementia with Lewy Bodies, mjff-assessing-aggregation-alpha-synuclein-across-aging-alzheimers-disease-and-dementia-lewy, 2025, 1 Jan 2025
Alzheimer's Drug Discovery Foundation
Diagnostics Accelerator, TABLOOD: a biomarker panel for direct assessment in blood of Alzheimer’s Disease pathophysiological hallmarks., ADDF-20972389, 2019–2021, 1 Aug 2019
Sources: reporter.nih.gov, openalex.org